MRD-guided therapy for CLL balances treatment cessation risks with cumulative toxicity concerns, offering a promising alternative to continuous or fixed-duration therapies. The VISION/HOVON141 trial ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis. The research focused on 2 primary ...

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of ...

Suchitra Sundaram, MD, describes the excitement around the American Society of Hematology (ASH) 2024 meeting in the chronic lymphocytic leukemia (CLL) community, with promising updates on innovative ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA The rates of complete ...

Suchitra Sundaram, MD, reviews new data on CLL treatments presented at ASH 2024, highlighting exciting possibilities for future patient care. She recounts the case of a 75-year-old man with worsening ...

MRD quantification allows for improved PFS prediction in both patients who achive PR and CR, which thus supports its application in all responders. In contrast to residual lymphadenopathy, persisting ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Adaptive Biotechnologies Corporation announced that its clonoSEQ® test for measurable residual disease (MRD) will be prominently featured in 30 presentations at the upcoming American Society of ...